Skip to main content

Table 3 Subgroup analysis of ORR, DCR, mDOR, mPFS and TRAes in mccRCC

From: The efficacy and safety of belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis

Subgroups

ORR

DCR

mDOR

mPFS

Grade 3–5 TRAes

N

ES

(95% CI)

I2(P)

Pa

N

ES

(95% CI)

I2(P)

Pa

N

ES

(95% CI)

I2(P)

Pa

N

ES

(95% CI)

I2(P)

Pa

N

ES

(95% CI)

I2(P)

Pa

Line of therapy

   

<0.01

   

<0.01

   

0.388

   

-

   

0.988

 First-line

1

70%

(56–81%)

  

1

98%

(90–100%)

  

1

28.6

(11.65–45.55)

  

0

   

1

46%

(33–60%)

  

 ≥ Second-line

6

26%

(21–32%)

43.51%

(0.12)

 

6

75%

(63–85%)

86.95%

(0.00)

 

3

20.41

(12.75–28.07)

17.2%

(0.299)

 

5

8.8

(6.15–11.44)

-

-

6

46%

(39–54%)

62.22%

(0.02)

 

Regimen in ≥ Second-line

   

0.014

   

0.177

   

0.131

   

-

   

0.002

 ≥ Second Single

4

23%

(20–27%)

0.00%

(0.96)

 

4

73%

(62–83%)

82.13%

(0.00)

 

2

17.26

(8.58–25.94)

0.0%

(0.716)

 

4

7.64

(5.36–9.91)

67.6%

(0.026)

 

4

41%

(37–45%)

0.00%

(0.45)

 

 ≥ Second Combination

2

37%

(26–48%)

  

2

83%

(73–91%)

  

1

31.5

(15.2–47.8)

  

1

13.8

(8.8–18.8)

  

2

59%

(48–69%)

  

Drug dosage

   

0.137

   

0.916

   

0.168

   

-

   

0.996

 120 mg

6

36%

(22–50%)

89.72%

(0.00)

 

6

79%

(64–92%)

92.82%

(0.00)

 

3

26.02

(16.81–35.24)

0.0%

(0.532)

 

4

8.85

(5.68–12.04)

79.9%

(0.002)

 

6

46%

(39–54%)

61.79%

(0.02)

 

 200 mg

1

23%

(15–34%)

  

1

78%

(68–86%)

  

1

16.10

(2.10–23.50)

  

1

9.1

(5.85–12.35)

  

1

46%

(36–57%)

  

IMDC risk group

   

0.374

   

0.041

            

 Favorable

5

41%

(18–66%)

78.11%

(0.00)

 

3

100%

(94–100%)

              

 Intermediate/poor

5

29%

(19–40%)

65.85%

(0.02)

 

3

87%

(75–96%)

              
  1. Note Pa Subgroup difference P value
  2. Abbreviations mccRCC advanced or metastatic clear cell renal cell carcinoma, ORR objective response rate, DCR disease control rate, mDOR median duration of response, mPFS median progression-free survival, TRAes treatment-related adverse events, IMDC International Metastatic Renal Cell Carcinoma Database Consortium, ES effect size, 95% CI 95% confidence interval
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us